5eqe: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='5eqe' size='340' side='right'caption='[[5eqe]], [[Resolution|resolution]] 2.40Å' scene=''> | <StructureSection load='5eqe' size='340' side='right'caption='[[5eqe]], [[Resolution|resolution]] 2.40Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5eqe]] is a 2 chain structure with sequence from [ | <table><tr><td colspan='2'>[[5eqe]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EQE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5EQE FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.4Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5R8:[4-[(4-METHYL-1,4-DIAZEPAN-1-YL)METHYL]PHENYL]METHANAMINE'>5R8</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5eqe FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5eqe OCA], [https://pdbe.org/5eqe PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5eqe RCSB], [https://www.ebi.ac.uk/pdbsum/5eqe PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5eqe ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/CHKA_HUMAN CHKA_HUMAN] Has a key role in phospholipid biosynthesis and may contribute to tumor cell growth. Catalyzes the first step in phosphatidylcholine biosynthesis. Contributes to phosphatidylethanolamine biosynthesis. Phosphorylates choline and ethanolamine. Has higher activity with choline.<ref>PMID:19915674</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 27: | Line 26: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Dalgarno | [[Category: Dalgarno DC]] | ||
[[Category: Zhou | [[Category: Zhou T]] | ||
[[Category: Zhu | [[Category: Zhu X]] | ||
Revision as of 11:16, 12 July 2023
Crystal structure of choline kinase alpha-1 bound by [4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine (compound 11)Crystal structure of choline kinase alpha-1 bound by [4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine (compound 11)
Structural highlights
FunctionCHKA_HUMAN Has a key role in phospholipid biosynthesis and may contribute to tumor cell growth. Catalyzes the first step in phosphatidylcholine biosynthesis. Contributes to phosphatidylethanolamine biosynthesis. Phosphorylates choline and ethanolamine. Has higher activity with choline.[1] Publication Abstract from PubMedCholine kinase alpha (ChoKalpha) is an enzyme involved in the synthesis of phospholipids, and thereby plays key roles in regulation of cell proliferation, oncogenic transformation and human carcinogenesis. Since several inhibitors of ChoKalpha display anti-proliferative activity in both cellular and animal models, this novel oncogene has recently gained interest as a promising small molecule target for cancer therapy. Here we summarize our efforts to further validate ChoKalpha as an oncogenic target, and explore the activity of novel small molecule inhibitors of ChoKalpha. Starting from weakly binding fragments, we describe a structure based lead discovery approach, which resulted in novel highly potent inhibitors of ChoKalpha. In cancer cell lines, our lead compounds exhibit a dose-dependent decrease of phosphocholine, inhibition of cell growth and induction of apoptosis at low micromolar concentrations. The drug-like lead series presented here is optimizable for improvements in cellular potency, drug target residence time, and pharmacokinetic parameters. These inhibitors may be utilized not only to further validate ChoKalpha as anti-oncogenic target, but also as novel chemical matter which may lead to anti-tumor agents that specifically interfere with cancer cell metabolism. Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-based Drug Discovery.,Zech SG, Kohlmann A, Zhou T, Li F, Squillache R, Parillon L, Greenfield M, Miller D, Qi J, Thomas M, Wang Y, Xu Y, Miret J, Shakespeare WC, Zhu X, Dalgarno DC J Med Chem. 2015 Dec 23. PMID:26700752[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||